Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tengion gets $50mm with Series B round

Executive Summary

Tengion (developing autologous neo-organs and tissues for the cardiovascular and genitourinary markets) has raised $50mm with its Series B venture round. Bain Capital (with funds from Brookside Capital) and Quaker BioVentures led the financing and were joined by all of the company's current backers, namely Oak Investment Partners, Johnson & Johnson Development Corp., HealthCap, and L Capital Partners. Tengion plans to use the proceeds to advance its autologous neo-bladder, and to develop a manufacturing facility in PA.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies